Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study
S. Reshwan K. Malahe, Rogier A.S. Hoek, Virgil A. S. H. Dalm, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e172-e178
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 51
Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023
Javier T Solera, Berta G. Árbol, Ankit Mittal, et al.
American Journal of Transplantation (2024) Vol. 24, Iss. 7, pp. 1303-1316
Open Access | Times Cited: 18
Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials
Adam C. Levine, Yuriko Fukuta, Moisés A. Huamán, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 12, pp. 2077-2086
Open Access | Times Cited: 40
Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study
Amita Ketkar, Vincent J. Willey, Lisa Glasser, et al.
Advances in Therapy (2024) Vol. 41, Iss. 3, pp. 1075-1102
Open Access | Times Cited: 11
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
Matthew Gagné, Barbara J. Flynn, Shayne F. Andrew, et al.
Nature Immunology (2024) Vol. 25, Iss. 10, pp. 1913-1927
Open Access | Times Cited: 10
COVID-19 Reinfection Has Better Outcomes Than the First Infection in Solid Organ Transplant Recipients
Javier T Solera, Berta G. Árbol, Ankit Mittal, et al.
Transplantation (2024)
Closed Access | Times Cited: 9
Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study
Sandra Rajme‐López, Bernardo Alfonso Martínez-Guerra, Jessica Zalapa‐Soto, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 10
Open Access | Times Cited: 31
Relationship Between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients: The CONTRAST Cohort
Cecilia Bonazzetti, Beatrice Tazza, Dino Gibertoni, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 10, pp. 1761-1767
Open Access | Times Cited: 22
Prognostic value of anti-SARS-CoV-2 antibodies: a systematic review
Sylvia Mink, Patrick Reimann, Peter Fraunberger
Clinical Chemistry and Laboratory Medicine (CCLM) (2024) Vol. 62, Iss. 6, pp. 1029-1043
Open Access | Times Cited: 9
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial
Arvind Gharbharan, Carlijn Jordans, Jaap Jan Zwaginga, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 2, pp. 208-214
Open Access | Times Cited: 26
Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use
Cosmo Del Borgo, Silvio Garattini, Carolina Bortignon, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 1025-1025
Open Access | Times Cited: 16
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 15
Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts
Louis Nevejan, Sien Ombelet, Lies Laenen, et al.
Viruses (2022) Vol. 14, Iss. 12, pp. 2736-2736
Open Access | Times Cited: 21
Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort)
Tommaso Manciulli, Michele Spinicci, Barbara Rossetti, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 438-438
Open Access | Times Cited: 13
Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study
Jennifer H. Ku, Lina S. Sy, Lei Qian, et al.
Vaccine (2023) Vol. 41, Iss. 24, pp. 3636-3646
Open Access | Times Cited: 13
Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
Benjamin Chen, Nina M. Haste, Nancy Binkin, et al.
PLoS ONE (2023) Vol. 18, Iss. 4, pp. e0275356-e0275356
Open Access | Times Cited: 11
SARS-CoV-2 Variants and Clinical Outcomes of Special Populations: A Scoping Review of the Literature
Achilleas Livieratos, Charalambos Gogos, Karolina Akinosoglou
Viruses (2024) Vol. 16, Iss. 8, pp. 1222-1222
Open Access | Times Cited: 4
COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics
Emily A. Rosen, Elizabeth M. Krantz, Denise J. McCulloch, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 11, pp. 1108.e1-1108.e11
Closed Access | Times Cited: 4
Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19
Lucia Graziani, Leonardo Gori, Tommaso Manciulli, et al.
Journal of Antimicrobial Chemotherapy (2022) Vol. 78, Iss. 2, pp. 555-558
Open Access | Times Cited: 18
Favorable outcomes of COVID‐19 in vaccinated hematopoietic stem cell transplant recipients: A single‐center experience
Jing Yuan Tan, Liang En Wee, Yi Hern Tan, et al.
Transplant Infectious Disease (2023) Vol. 25, Iss. 3
Closed Access | Times Cited: 10
Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future
David A. Van Eijndhoven, Robin Vos, Saskia Bos
Transplant International (2025) Vol. 38
Open Access
Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study
Flavia Petrucci, Chiara Pellicano, Francesco Cogliati Dezza, et al.
Viruses (2025) Vol. 17, Iss. 2, pp. 274-274
Open Access
Clinical outcomes in immunocompromised adults with COVID-19, based on anti-spike IgG serostatus and monoclonal antibody therapy: a retrospective cohort study in the Omicron period
Shilpa Vasishta, Judith A. Aberg, Gopi Patel, et al.
Therapeutic Advances in Infectious Disease (2025) Vol. 12
Open Access
Real-World Experience with the Available Outpatient COVID-19 THErapies in Patients with canceR (CO.THER)
Angioletta Lasagna, Giulia Gambini, Catherine Klersy, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 999-999
Open Access
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective
Paul Loubet, Iliès Benotmane, Slim Fourati, et al.
Infectious Diseases and Therapy (2025)
Open Access
Page 1 - Next Page

Scroll to top